ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC)

BACKGROUND: Previous studies have provided a comprehensive picture of genomic alterations in primary and metastatic Hormone Receptor (HR)-positive, Human Epidermal growth factor Receptor 2 (HER2)-negative breast cancer (HR+ HER2- BC). However, the evolution of the genomic landscape of HR+ HER2- BC d...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrando, Lorenzo, Vingiani, Andrea, Garuti, Anna, Vernieri, Claudio, Belfiore, Antonino, Agnelli, Luca, Dagrada, Gianpaolo, Ivanoiu, Diana, Bonizzi, Giuseppina, Munzone, Elisabetta, Lippolis, Luana, Dameri, Martina, Ravera, Francesco, Colleoni, Marco, Viale, Giuseppe, Magnani, Luca, Ballestrero, Alberto, Zoppoli, Gabriele, Pruneri, Giancarlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839248/
https://www.ncbi.nlm.nih.gov/pubmed/36595552
http://dx.doi.org/10.1371/journal.pgen.1010563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839248/
https://www.ncbi.nlm.nih.gov/pubmed/36595552
http://dx.doi.org/10.1371/journal.pgen.1010563

Ejemplares similares